2021
Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
Lockshin B, Cronin A, Harrison R, McLean R, Anatale‐Tardiff L, Burge R, Zhu B, Malatestinic W, Atiya B, Murage M, Gallo G, Strober B, Van Voorhees A. Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry. Dermatologic Therapy 2021, 34: e14808. PMID: 33491259, PMCID: PMC8047872, DOI: 10.1111/dth.14808.Peer-Reviewed Original ResearchConceptsCorrona Psoriasis RegistryIL-17 inhibitorsIL-17iTNF inhibitorsReal-world patientsDrug survivalHazard ratioPsoriasis RegistryDrug discontinuationDrug initiationLower riskBiologic experienceIxekizumab groupsPsO patientsSevere PsONaïve patientsMean ageIxekizumabPatientsReal-world settingDiscontinuationPsoriasisSurvivalRegistryInhibitors
2010
Benefit‐risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis
Langley R, Strober B, Gu Y, Rozzo S, Okun M. Benefit‐risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. British Journal Of Dermatology 2010, 162: 1349-1358. PMID: 20394634, DOI: 10.1111/j.1365-2133.2010.09707.x.Peer-Reviewed Original ResearchConceptsTumor necrosis factorAdverse eventsTumor necrosis factor antagonistsMalignant adverse eventsOpen-label dataPlacebo-controlled periodAnti-TNF therapyNecrosis factor antagonistsTreatment of psoriasisTreatment effect dataBenefit-risk balanceBenefit-risk assessmentTNF antagonistsNNT valuesEfficacy measuresClinical trialsNecrosis factorSerious toxicitySafety dataFactor antagonistsLower riskEtanerceptPsoriasisAdalimumabInfliximab